Jump to content

Search the Community

Showing results for tags 'metastasis'.

More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


    • Announcements, meetings and other resources
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...

Date Created

  • Start


Last Updated

  • Start


Filter by number of...

Found 4 results

  1. Jim Marshall (not a doctor) said ... Metastases (mets) are cancers growing away from the original cancer. In prostate cancer, metastases are often found growing in bone. This can become very painful. A common treatment for a painful met is a strong dose of radiation (X-rays) focussed on the met. A special problem arises at the end of life. No one wants to give a treatment that won't work in time. So Rachel McDonald and her colleagues looked at how quickly radiation to one or two mets gave pain relief and a better quality of life. The answer: Men who responded (around 40%) reported significant pain relief at day 10, and a greater quality of life at day 42 in a number of ways. The authors conclusion: ... end Jim The link below is to a page or document that we do not control. Parts of it may be wrong or misleading. Check with your doctor if something interests you. You may need to subscribe to the site to view the article. If it is temporarily or permanently unavailable, you may receive an error message. http://jamanetwork.com/journals/jamaoncology/article-abstract/2601221
  2. Click on this link to read the article in Scientific American.
  3. Research performed at the University of Queensland has shown that a diet, which is high in cholesterol, might increase the spread of prostate cancer tumours to lymph nodes, lungs and bones. Click here to read news article.
  4. Paul Edwards

    Cabozantinib - COMET-2 Clinical Trial

    Thanks to Russ Wilson for pointing out that a clinical trial of Cabozantinib is currently recruiting in Queensland, New South Wales, Victoria and Western Australia for men with metastatic hormone-refractory prostate cancer who have had chemotherapy. Cabozantinib (marketed under the tradename Cometriq, formerly known as XL184) has been shown to reduce tumor growth, metastasis and angiogenesis. It was approved by the U.S. FDA in November 2012 for the treatment of medullary thyroid cancer. It is currently undergoing clinical trials for the treatment of prostate, ovarian, brain, melanoma, breast, non-small cell lung, pancreatic, hepatocellular and kidney cancers. Whilst previous clinical trials on men with metastatic, castration-resistant prostate cancer have shown a significant reduction in bone-related pain and other improvements in quality of life, a number of serious potential adverse effects have been observed. The clinical trial which is recruiting in Australia is the Study of Cabozantinib Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2) Click this link for more details. There are currently clinical trials in the US looking at the use of Cabozantinib for prostate cancer before chemotherapy, either in combination with abiraterone or with hormone therapy.
  • Create New...